pyruvic acid has been researched along with Carcinoma, Hepatocellular in 23 studies
Pyruvic Acid: An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed)
pyruvic acid : A 2-oxo monocarboxylic acid that is the 2-keto derivative of propionic acid. It is a metabolite obtained during glycolysis.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Following hyperpolarized [1-(13)C]pyruvate injections, pyruvate and its metabolic products, alanine and lactate, were observed in the liver of five rats with hepatocellular carcinoma and five healthy control rats." | 3.76 | T(2) relaxation times of (13)C metabolites in a rat hepatocellular carcinoma model measured in vivo using (13)C-MRS of hyperpolarized [1-(13)C]pyruvate. ( Butts Pauly, K; Hurd, R; King, R; Le Roux, P; Mayer, D; Pfefferbaum, A; Spielman, D; Tropp, J; Vasanawala, S; Yen, YF, 2010) |
| " To investigate this hypothesis, we compared the response to an anticancer agent chloroethylnitrosourea (CENU) of two transformed cell lines: HepG2 (hepatocarcinoma) with a partially differentiated phenotype and 143B (osteosarcoma) with an undifferentiated one." | 3.75 | Mitochondrial bioenergetic background confers a survival advantage to HepG2 cells in response to chemotherapy. ( Chevrollier, A; Demidem, A; Douay, O; Loiseau, D; Morvan, D; Reynier, P; Stepien, G, 2009) |
| " In summary, the results demonstrate that pyruvate metabolism acts as novel targetable metabolic vulnerabilities for HCC treatment in combination with a glutamine-deficient diet." | 1.72 | Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment. ( Bao, MH; Chan, CY; Chen, Y; Lee, D; Tse, AP; Wei, L; Wong, BP; Wong, CC; Yang, C; Yuen, VW; Zhang, MS, 2022) |
| "Follow-up screening was performed in hepatocellular carcinoma with a focused CRISPR library targeting imaging-related genes." | 1.56 | Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer. ( Ackerman, D; Gade, TPF; Johnson, O; Mercadante, M; Perkons, NR; Pilla, G; Profka, E, 2020) |
| "Human hepatocellular carcinoma cells Huh7 and alveolar epithelial cells A549 were stimulated with either interleukin (IL) IL-1β (1 ng/ml, 24 h) or tumor necrosis factor (TNF) (10 ng/ml, 4 h), and then treated with EtP (2." | 1.43 | Ethanol, ethyl and sodium pyruvate decrease the inflammatory responses of human lung epithelial cells via Akt and NF-κB in vitro but have a low impact on hepatocellular cells. ( Juengel, E; Marzi, I; Mörs, K; Omid, N; Perl, M; Relja, B; Wagner, N; Werner, I, 2016) |
| "These data indicated that AS-30D hepatoma cells had a predominantly oxidative and not a glycolytic type of metabolism." | 1.31 | Substrate oxidation and ATP supply in AS-30D hepatoma cells. ( Moreno-Sánchez, R; Rodríguez-Enríquez, S; Torres-Márquez, ME, 2000) |
| "We have shown previously that rat hepatoma FTO-2B cells express two mRNAs, called F (fetal) and L (liver), from distinct promoters of the same gene coding for 6-phosphofructo-2-kinase (PFK-2)." | 1.30 | Glucose response elements in a gene that codes for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. ( Dupriez, VJ; Rousseau, GG, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 5 (21.74) | 29.6817 |
| 2010's | 10 (43.48) | 24.3611 |
| 2020's | 5 (21.74) | 2.80 |
| Authors | Studies |
|---|---|
| Kim, H | 1 |
| Lee, HJ | 1 |
| Sim, DY | 1 |
| Park, JE | 1 |
| Ahn, CH | 1 |
| Park, SY | 2 |
| Jang, E | 1 |
| Kim, B | 1 |
| Kim, SH | 1 |
| Gnocchi, D | 1 |
| Kurzyk, A | 1 |
| Mintrone, A | 1 |
| Lentini, G | 1 |
| Sabbà, C | 1 |
| Mazzocca, A | 1 |
| Yang, C | 1 |
| Lee, D | 1 |
| Zhang, MS | 1 |
| Tse, AP | 1 |
| Wei, L | 1 |
| Bao, MH | 1 |
| Wong, BP | 1 |
| Chan, CY | 1 |
| Yuen, VW | 1 |
| Chen, Y | 1 |
| Wong, CC | 1 |
| Shi, Q | 1 |
| Xue, C | 1 |
| Zeng, Y | 1 |
| Gu, X | 1 |
| Wang, J | 1 |
| Li, L | 1 |
| Tompkins, SC | 1 |
| Sheldon, RD | 1 |
| Rauckhorst, AJ | 1 |
| Noterman, MF | 1 |
| Solst, SR | 1 |
| Buchanan, JL | 1 |
| Mapuskar, KA | 1 |
| Pewa, AD | 1 |
| Gray, LR | 1 |
| Oonthonpan, L | 1 |
| Sharma, A | 1 |
| Scerbo, DA | 1 |
| Dupuy, AJ | 2 |
| Spitz, DR | 1 |
| Taylor, EB | 1 |
| Perkons, NR | 1 |
| Johnson, O | 1 |
| Pilla, G | 1 |
| Profka, E | 1 |
| Mercadante, M | 1 |
| Ackerman, D | 1 |
| Gade, TPF | 1 |
| Kim, J | 1 |
| Yu, L | 1 |
| Chen, W | 1 |
| Xu, Y | 2 |
| Wu, M | 1 |
| Todorova, D | 1 |
| Tang, Q | 1 |
| Feng, B | 1 |
| Jiang, L | 1 |
| He, J | 1 |
| Chen, G | 1 |
| Fu, X | 1 |
| Cipolleschi, MG | 1 |
| Marzi, I | 2 |
| Santini, R | 1 |
| Fredducci, D | 1 |
| Vinci, MC | 1 |
| D'Amico, M | 1 |
| Rovida, E | 1 |
| Stivarou, T | 1 |
| Torre, E | 1 |
| Dello Sbarba, P | 1 |
| Stecca, B | 1 |
| Olivotto, M | 1 |
| Bard-Chapeau, EA | 1 |
| Nguyen, AT | 1 |
| Rust, AG | 1 |
| Sayadi, A | 1 |
| Lee, P | 1 |
| Chua, BQ | 1 |
| New, LS | 1 |
| de Jong, J | 1 |
| Ward, JM | 1 |
| Chin, CK | 1 |
| Chew, V | 1 |
| Toh, HC | 1 |
| Abastado, JP | 1 |
| Benoukraf, T | 1 |
| Soong, R | 1 |
| Bard, FA | 1 |
| Johnson, RL | 1 |
| Radda, GK | 1 |
| Chan, EC | 1 |
| Wessels, LF | 1 |
| Adams, DJ | 1 |
| Jenkins, NA | 1 |
| Copeland, NG | 1 |
| Relja, B | 1 |
| Omid, N | 1 |
| Wagner, N | 1 |
| Mörs, K | 1 |
| Werner, I | 1 |
| Juengel, E | 1 |
| Perl, M | 1 |
| Brandt, AP | 1 |
| Gozzi, GJ | 1 |
| Pires, Ado R | 1 |
| Martinez, GR | 1 |
| Dos Santos Canuto, AV | 1 |
| Echevarria, A | 1 |
| Di Pietro, A | 1 |
| Cadena, SM | 1 |
| Ho, HY | 1 |
| Cheng, ML | 1 |
| Chiu, HY | 1 |
| Weng, SF | 1 |
| Chiu, DT | 1 |
| Loiseau, D | 1 |
| Morvan, D | 1 |
| Chevrollier, A | 1 |
| Demidem, A | 1 |
| Douay, O | 1 |
| Reynier, P | 1 |
| Stepien, G | 1 |
| Yen, YF | 2 |
| Le Roux, P | 1 |
| Mayer, D | 2 |
| King, R | 1 |
| Spielman, D | 1 |
| Tropp, J | 1 |
| Butts Pauly, K | 1 |
| Pfefferbaum, A | 2 |
| Vasanawala, S | 1 |
| Hurd, R | 1 |
| Jung, SY | 1 |
| Song, HS | 1 |
| Chung, SH | 1 |
| Kim, YJ | 1 |
| Darpolor, MM | 1 |
| Chua, MS | 1 |
| Xing, L | 1 |
| Clarke-Katzenberg, RH | 1 |
| Shi, W | 1 |
| Josan, S | 1 |
| Hurd, RE | 1 |
| Senadheera, L | 1 |
| So, S | 1 |
| Hofmann, LV | 1 |
| Glazer, GM | 1 |
| Spielman, DM | 1 |
| Ouattara, DA | 1 |
| Prot, JM | 1 |
| Bunescu, A | 1 |
| Dumas, ME | 1 |
| Elena-Herrmann, B | 1 |
| Leclerc, E | 1 |
| Brochot, C | 1 |
| Perrin, A | 2 |
| Roudier, E | 2 |
| Duborjal, H | 1 |
| Bachelet, C | 2 |
| Riva-Lavieille, C | 1 |
| Leverve, X | 1 |
| Massarelli, R | 1 |
| Weiss, P | 1 |
| Ashwell, G | 1 |
| Morell, AG | 1 |
| Stockert, RJ | 1 |
| Dupriez, VJ | 1 |
| Rousseau, GG | 1 |
| Rodríguez-Enríquez, S | 1 |
| Torres-Márquez, ME | 1 |
| Moreno-Sánchez, R | 1 |
| Mizobuchi, N | 1 |
| Kuwao, F | 1 |
| Takeda, I | 1 |
| Takemura, T | 1 |
| Morita, S | 1 |
| Horimi, T | 1 |
| Takahashi, I | 1 |
23 other studies available for pyruvic acid and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
The Antitumor Effect of Cinnamaldehyde Derivative CB-PIC in Hepatocellular Carcinoma Cells via Inhibition of Pyruvate and STAT3 Signaling.
Topics: Acrolein; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; HCT116 Cells; Humans; Liver Neopla | 2022 |
Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Glycolysis; Humans; Lactic Acid; Liver Neoplasms; Oxidative Phosphorylati | 2022 |
Genome-Wide CRISPR/Cas9 Library Screening Revealed Dietary Restriction of Glutamine in Combination with Inhibition of Pyruvate Metabolism as Effective Liver Cancer Treatment.
Topics: Animals; Carcinoma, Hepatocellular; CRISPR-Cas Systems; Early Detection of Cancer; Glutamine; Liver | 2022 |
A novel prognostic model for hepatocellular carcinoma based on pyruvate metabolism-related genes.
Topics: Carcinoma, Hepatocellular; DNA Copy Number Variations; Humans; Liver Neoplasms; Prognosis; Pyruvic A | 2023 |
Disrupting Mitochondrial Pyruvate Uptake Directs Glutamine into the TCA Cycle away from Glutathione Synthesis and Impairs Hepatocellular Tumorigenesis.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Citric Acid Cycle; | 2019 |
Functional Genetic Screening Enables Theranostic Molecular Imaging in Cancer.
Topics: Animals; Carbon-13 Magnetic Resonance Spectroscopy; Carcinoma, Hepatocellular; CRISPR-Cas Systems; D | 2020 |
Wild-Type p53 Promotes Cancer Metabolic Switch by Inducing PUMA-Dependent Suppression of Oxidative Phosphorylation.
Topics: A549 Cells; Animals; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Proliferation; G | 2019 |
Hypoxia-resistant profile implies vulnerability of cancer stem cells to physiological agents, which suggests new therapeutic targets.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Citric Ac | 2014 |
Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model.
Topics: Animals; Carcinoma, Hepatocellular; Disease Models, Animal; DNA Transposable Elements; Gene Expressi | 2014 |
Ethanol, ethyl and sodium pyruvate decrease the inflammatory responses of human lung epithelial cells via Akt and NF-κB in vitro but have a low impact on hepatocellular cells.
Topics: bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Epithelial Cells; Ethanol; | 2016 |
Impairment of oxidative phosphorylation increases the toxicity of SYD-1 on hepatocarcinoma cells (HepG2).
Topics: Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Hep G2 Cells; Hepatocytes; | 2016 |
Dehydroepiandrosterone induces growth arrest of hepatoma cells via alteration of mitochondrial gene expression and function.
Topics: Adenosine Triphosphate; Carcinoma, Hepatocellular; Cell Proliferation; Dehydroepiandrosterone; DNA, | 2008 |
Mitochondrial bioenergetic background confers a survival advantage to HepG2 cells in response to chemotherapy.
Topics: Adenosine Triphosphate; Carcinoma, Hepatocellular; Cell Differentiation; Cell Proliferation; Cell Re | 2009 |
T(2) relaxation times of (13)C metabolites in a rat hepatocellular carcinoma model measured in vivo using (13)C-MRS of hyperpolarized [1-(13)C]pyruvate.
Topics: Alanine; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Disease Models, Animal; Liver Neoplasm | 2010 |
Pyruvate promotes tumor angiogenesis through HIF-1-dependent PAI-1 expression.
Topics: Blotting, Western; Carcinoma, Hepatocellular; Cells, Cultured; Electrophoretic Mobility Shift Assay; | 2011 |
In vivo MRSI of hyperpolarized [1-(13)C]pyruvate metabolism in rat hepatocellular carcinoma.
Topics: Alanine; Animals; Carbon Isotopes; Carcinoma, Hepatocellular; Gene Expression Regulation, Neoplastic | 2011 |
Metabolomics-on-a-chip and metabolic flux analysis for label-free modeling of the internal metabolism of HepG2/C3A cells.
Topics: Carcinoma, Hepatocellular; Cell Line; Cell Respiration; Citric Acid Cycle; Energy Metabolism; Glycol | 2012 |
Pyruvate reverses metabolic effects produced by hypoxia in glioma and hepatoma cell cultures.
Topics: Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Glioma; Glucose; Humans; Hypoxia | 2002 |
Pyruvate reduces DNA damage during hypoxia and after reoxygenation in hepatocellular carcinoma cells.
Topics: Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Comet Assay; DNA Damage; Glutathione; Hum | 2007 |
Modulation of the asialoglycoprotein receptor in human hepatoma cells: effect of glucose.
Topics: Asialoglycoprotein Receptor; Asialoglycoproteins; Binding Sites; Carcinoma, Hepatocellular; Culture | 1994 |
Glucose response elements in a gene that codes for 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase.
Topics: Animals; Carcinoma, Hepatocellular; Dactinomycin; Enhancer Elements, Genetic; Enzyme Inhibitors; Gen | 1997 |
Substrate oxidation and ATP supply in AS-30D hepatoma cells.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adenosine Triphosphate; Animals; Carcinoma, Hepatocellular; Ce | 2000 |
[Changes in ketone body ratio and levels of pyruvate and lactate in arterial blood of patients with hepatocellular carcinoma after transcatheter arterial embolization].
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Ketones; Lactates; Lactic Acid; Liver; | 1990 |